#United States #New York #Class Action #Pomerantz LLP #uniQure N.V.

Investor Alert: Pomerantz Law Firm Notifications

Pomerantz LLP, a leader in the field of securities class action litigation, has taken significant action by announcing a class action lawsuit against uniQure N.V., a well-known biotechnology firm. The lawsuit has been initiated for the benefit of investors who have incurred losses on their investments in uniQure securities, particularly those affected from the period in which the company's stock was traded on NASDAQ under the symbol QURE.

Background of the Case

The class action lawsuit raises critical allegations of securities fraud and other unlawful business practices allegedly conducted by uniQure and certain of its executives. Investors who have experienced financial losses during the relevant class period are encouraged to act before the stipulated deadline of April 13, 2026, to have their claims considered within the legal proceedings. Interested investors should reach out to Danielle Peyton at Pomerantz LLP for guidance on how to proceed.

Details of the Lawsuit

The legal complaint focuses on a series of communications made by uniQure regarding its investigational gene therapy treatment, AMT-130, designed for Huntington’s disease. The company had previously announced that it had received initial feedback from the U.S. Food and Drug Administration (FDA) during a pre-Biologics License Application (BLA) meeting. However, this feedback indicated a pivotal change in the FDA's stance regarding the adequacy of the data from Phase I/II studies, which called into question the basis for uniQure's BLA submission.

On November 3, 2025, after the press release detailing these developments, uniQure's stock price took a dramatic downturn, plummeting by $33.40 per share or approximately 49.34%. This substantial loss emphasizes the potential implications of the lawsuit and the need for affected investors to participate in the class action.

Pomerantz LLP’s Role

Founded more than 85 years ago, Pomerantz LLP has established itself as one of the premier firms specializing in various types of class action lawsuits including securities, corporate, and antitrust. They have a strong history of advocating for victims of corporate fraud, which further strengthens the case of the investors seeking justice against uniQure.

Next Steps for Investors

Investors are advised to contact Pomerantz LLP by sending an email to [email protected] or by calling the firm's office directly at 646-581-9980 (toll-free at 888-4-POMLAW) to inquire about their eligibility to join the class action. When reaching out, they should include their mailing address, phone number, and number of shares purchased for the firm's records.

In conclusion, this class action presents an essential opportunity for investors impacted by uniQure's recent activities to regain their losses. The forthcoming deadlines must not be overlooked, as they could determine the extent of recovery for aggrieved shareholders.

For further information, the Complaint and additional details regarding the class action can be accessed at pomerantzlaw.com. This situation serves as a critical reminder of the ongoing challenges in the biotech sector and the importance of investor vigilance. Stay informed and act promptly to protect your rights as a shareholder.